Medicine:MDX-1097

From HandWiki

MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer.[1] It is a chimeric version of the mouse monoclonal antibody K-1-21.[2] MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells.[3][4]

MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd.[4] In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.[5][6]

References

  1. ↑ "Australian New Zealand Clinical Trials Registry Number12616001164482". https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371289. 
  2. ↑ "Characterization of a unique conformational epitope on free immunoglobulin kappa light chains that is recognized by an antibody with therapeutic potential". Molecular Immunology 48 (9–10): 1245–52. May 2011. doi:10.1016/j.molimm.2011.03.003. PMID 21466897. 
  3. ↑ "Free Ig light chains interact with sphingomyelin and are found on the surface of myeloma plasma cells in an aggregated form". Journal of Immunology 185 (7): 4179–88. Oct 2010. doi:10.4049/jimmunol.1001956. PMID 20817866. 
  4. ↑ 4.0 4.1 Hutchinson, A. T.; Jones, D. R.; Raison, R. L. (2015). "Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma". Molecular Immunology 67 (2 Pt A): 89–94. doi:10.1016/j.molimm.2015.04.013. PMID 25964097. 
  5. ↑ "Immune System Therapeutics Circular to Creditors 25 May 2015". https://www.mcgrathnicol.com/app/uploads/Circular-to-creditors-25-May-20151.pdf. 
  6. ↑ "Haemalogix Website - MDX-1097 Clinical Trials". http://www.haemalogix.com/science/clinical-trials/5. 





Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:MDX-1097&oldid=389022"